Curcumin Biomarkers
キーワード
概要
日付
| 最終確認済み: | 12/31/2012 |
| 最初に提出された: | 04/05/2011 |
| 提出された推定登録数: | 04/10/2011 |
| 最初の投稿: | 04/11/2011 |
| 最終更新が送信されました: | 02/05/2013 |
| 最終更新日: | 02/06/2013 |
| 実際の研究開始日: | 10/31/2010 |
| 一次完了予定日: | 09/30/2011 |
| 研究完了予定日: | 12/31/2012 |
状態または病気
介入/治療
Drug: Curcumin
段階
アームグループ
| 腕 | 介入/治療 |
|---|---|
| Experimental: Curcumin 4g Curcumin C3 tablet daily | Drug: Curcumin 4 grams Curcumin C3 tablet daily x30 days |
適格基準
| 研究の対象となる年齢 | 40 Years に 40 Years |
| 研究に適格な性別 | All |
| 健康なボランティアを受け入れる | はい |
| 基準 | Inclusion Criteria: 1. Age 40 - 80. 2. A willingness to follow the study protocol, as indicated by provision of informed consent to participate 3. Good general health Exclusion Criteria: 1. Familial colorectal cancer syndromes (e.g. Hereditary Non-Polyposis Colon Cancer, Familial Adenomatous Polyposis) 2. Ulcerative colitis or Crohn's disease. 3. History of large bowel resection for any reason 4. Diagnosed narcotic or alcohol dependence 5. Unwillingness to forgo curcumin/turmeric-containing supplements during the trial or consumption of curry/turmeric at meals > 3 times a week. 6. Allergy to turmeric/curcumin. 7. Women with childbearing potential who do not agree to practice effective birth control. 8. Individuals with creatinine, AST or ALT above 1.5 times the upper limit of normal at baseline. 9. Personal or inherited bleeding disorders or therapeutic anti-coagulation with warfarin. 10. Women who are pregnant or nursing. 11. Individuals who have taken antibiotics within the three months prior to enrollment. |
結果
主な結果の測定
1. Gene expression [30 days]
2. Ribonucleic acid (RNA) level [30 days]
3. Apoptosis [30 days]
二次的な結果の測定
1. Number of Participants with Adverse Events [30 days]
